467. Natural human interferon-beta plus ribavirin treatment toleration by chronic hepatitis C patients with depression or thrombocytopenia
Session: Poster Abstract Session: Prevention and Treatment of Viral Infections
Thursday, October 3, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • IDweek 2013 No467 ikezaki.pdf (275.6 kB)
  • Background:

    Natural human interferon-beta (nIFN-beta) seldom causes neurological adverse effects and is recommended for depressive patients with chronic hepatitis C. It also does not often cause thrombocytopenia, in contrast to pegylated interferon-alpha (PEG-IFN-alpha), which often causes thrombocytopenia. Limited data has been reported comparing nIFN-beta and PEG-IFN-alpha when ribavirin (RBV) is combined. This case-control study was done to compare the efficacy adverse effects of a combination of nIFN-beta or PEG-IFN-alpha plus RBV for chronic hepatitis C patients.

    Methods:

    Sixty patients (42 hepatitis C virus genotype 1 and 18 genotype 2) were treated with nIFN-beta plus RBV (48 week course for genotype 1 and 24 week course for genotype 2). Of them, 23 (38.3%) suffered pre-treatment severe depression. Their data was compared with that of 60 age-, sex-, and genotype-matched patients who were treated with PEG-IFN-alpha plus RBV treatment for the same treatment periods. None of the patients in the PEG-IFN-alpha treated group suffered pre-treatment depression.

    Results:

    Sustained virological response rates did not significantly differ between the nIFN-beta and PEG-IFN-alpha treated groups (genotype 1, 21.4 % vs. 33.3 %, P=0.328; genotype 2, 72.2 % vs. 88.9 %, respectively, P=0.402). None of the nIFN-beta-treated patients showed exacerbation of depression or malaise, but 7 (11.7%) of 60 PEG-IFN-alpha treated patients developed severe malaise. The mean percentage of platelet count decrease from baseline to the week 4 of treatment significantly differed between the nIFN-beta and PEG-IFN-alpha groups (-7.1% vs. -26.2%) (P<0.001). Among patients with a baseline platelet count <120×109/L, the percentage of decrease to <80×109/L at week 4 was significantly lower at 50.0% (14 of 28) of the nIFN-beta-treated group than at 88.9% (8 of 9) of the PEG-IFN-alpha-treated group (P=0.035).

    Conclusion:

    nIFN-beta plus RBV treatment was well tolerated by chronic hepatitis C patients with depression or thrombocytopenia.

    Hiroaki Ikezaki, MD., Norihiro Furusyo, MD., PhD., Satoshi Hiramine, MD., Eiichi Ogawa, MD., PhD., Masayuki Murata, MD., PhD. and Jun Hayashi, MD., PhD., Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan

    Disclosures:

    H. Ikezaki, None

    N. Furusyo, None

    S. Hiramine, None

    E. Ogawa, None

    M. Murata, None

    J. Hayashi, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.